Finanalist schreef op 1 april 2021 11:14:
Edison note 1 april 2021
Acacia Pharma Full-year results
BARHEMSYS and BYFAVO launched in the US
Valuation: €1,278m or €12.8/share
The year 2020 was transformational for Acacia Pharma, with the US
approval of its two lead assets, BARHEMSYS (amisulpride injection) for
the treatment and prevention of post-operative nausea and vomiting
(PONV) and BYFAVO (remimazolam), an IV sedative for use during invasive
medical procedures. Both assets have now been launched, BARHEMSYS
in August 2020 and BYFAVO in January 2021. By marketing two products
through a small but experienced salesforce, Acacia should realise
significant operational synergies. Launches are in the early phase, with the
focus on gaining wide formulary access in FY21; this should translate to
significant revenue generation from FY22 onwards and maiden operating
profit from FY23. Our updated valuation of Acacia Pharma is €1,278m.